Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV...

33

Transcript of Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV...

Page 1: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 2: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 3: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 4: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 5: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 6: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 7: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 8: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 9: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 10: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 11: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 12: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 13: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 14: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 15: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 16: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 17: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 18: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 19: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 20: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 21: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 22: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 23: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 24: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 25: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 26: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 27: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 28: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 29: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 30: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 31: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 32: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to
Page 33: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to

Thumbnail - Startseite...9.7 assessment of Large Versus small Molecules in CV sP 147 9.7.1 Introduction147 9.7.2 CV sP Evaluation 147 9.8 Patients do not Necessarily Respond to Drugs

Thumbnail - Startseite...9.7 assessment of Large Versus small Molecules in CV sP 147 9.7.1 Introduction147 9.7.2 CV sP Evaluation 147 9.8 Patients do not Necessarily Respond to Drugs

Tehran University of Medical Sciences Contact Information ...sinahospital.tums.ac.ir/images/editor/File/pdf/CV asatid/CV latin... · 2002 – Present Association for Supporting Patients

Tehran University of Medical Sciences Contact Information ...sinahospital.tums.ac.ir/images/editor/File/pdf/CV asatid/CV latin... · 2002 – Present Association for Supporting Patients

Management of Diabetes in CV patients · 2019-06-21 · •NICE-Sugar study •6104 patients –Mean age ~60 years old, 20% with history of diabetes –Admission to ICU (~37% with

Management of Diabetes in CV patients · 2019-06-21 · •NICE-Sugar study •6104 patients –Mean age ~60 years old, 20% with history of diabetes –Admission to ICU (~37% with

Cardiology in General Practice (Nov 2018) in... · Investigated CV mortality and hospitalization Randomised trial, 3023 patients. Candesartan VS placebo.in patients with HFpEF. No

Cardiology in General Practice (Nov 2018) in... · Investigated CV mortality and hospitalization Randomised trial, 3023 patients. Candesartan VS placebo.in patients with HFpEF. No

Predictors of cardiovascular events in patients with ...download.xuebalib.com/5iuchB2d96Ll.pdf · Predictors of CV events in hypertensives with LVH 349 stroke (n 443 from 8465 patients)

Predictors of cardiovascular events in patients with ...download.xuebalib.com/5iuchB2d96Ll.pdf · Predictors of CV events in hypertensives with LVH 349 stroke (n 443 from 8465 patients)

Review Article Sacubitril/Valsartan in Asian Patients with Heart … · 2019-06-05 · endpoint of all-cause death and CV hospitalization was seen in patients randomized to receive

Review Article Sacubitril/Valsartan in Asian Patients with Heart … · 2019-06-05 · endpoint of all-cause death and CV hospitalization was seen in patients randomized to receive

5th Annual Quality & Safety Symposium Q... · cardiovascular (CV) events, including CV death, heart failure (HF) hospitalization and slow progression of kidney disease (CKD) in patients

5th Annual Quality & Safety Symposium Q... · cardiovascular (CV) events, including CV death, heart failure (HF) hospitalization and slow progression of kidney disease (CKD) in patients

APPROVED MINUTES OF THE FINANCE & PERSONNEL … · PH Director S. Galoff presented a financial projection estimating that the County may save $10,305 a year in wage & health insurance

APPROVED MINUTES OF THE FINANCE & PERSONNEL … · PH Director S. Galoff presented a financial projection estimating that the County may save $10,305 a year in wage & health insurance

Depression and CV Disease A Depressing Storyassets.escardio.org/assets/Presentations/OTHER2011/Davos/...Depression and CV Disease Approximately 50% of patients with MDD have an adequate

Depression and CV Disease A Depressing Storyassets.escardio.org/assets/Presentations/OTHER2011/Davos/...Depression and CV Disease Approximately 50% of patients with MDD have an adequate

Now or Never: The Cardiologist’s Role in Improving CV Outcomes in Patients With Type 2 Diabetes

Now or Never: The Cardiologist’s Role in Improving CV Outcomes in Patients With Type 2 Diabetes

MHIF FEATURED STUDY: AEGIS 2 Please Refer Patients to Steph! · Please Refer Patients to Steph! 5 of 56. MHIF CV Grand Rounds –Sept. 10, 2018 Nuclear Cardiology: Beyond perfusion

MHIF FEATURED STUDY: AEGIS 2 Please Refer Patients to Steph! · Please Refer Patients to Steph! 5 of 56. MHIF CV Grand Rounds –Sept. 10, 2018 Nuclear Cardiology: Beyond perfusion

Safety Assessment in Clinical Trials and Beyond · Type 2 DM at high CV risk – 7020 total patients observed over median of 3.1 years – Primary composite outcome - death from CV

Safety Assessment in Clinical Trials and Beyond · Type 2 DM at high CV risk – 7020 total patients observed over median of 3.1 years – Primary composite outcome - death from CV

STATE OF CONNECTICUT - cga.ct.gov services, department... · 11/15/2018 · Consumers Living at Home 10,305 10,380 10,821 Consumers in Public Residential Settings 861 798 741 Consumers

STATE OF CONNECTICUT - cga.ct.gov services, department... · 11/15/2018 · Consumers Living at Home 10,305 10,380 10,821 Consumers in Public Residential Settings 861 798 741 Consumers

Curriculum vitae (CV) - infectious.sbmu.ac.irinfectious.sbmu.ac.ir/uploads/321_2007_1534835973396_CV-New-2018.pdf · B.TTV virus infection in hemodialysis patients: A seroepidemiological

Curriculum vitae (CV) - infectious.sbmu.ac.irinfectious.sbmu.ac.ir/uploads/321_2007_1534835973396_CV-New-2018.pdf · B.TTV virus infection in hemodialysis patients: A seroepidemiological

Optimizing CV Risk in Hospitalized Patients - tri-ist.com IST PDFs of PPTs/Day 2... · Optimizing CV Risk in Hospitalized Patients ... A patient had an NSTEMI with a ... Lp-PLA2 Thrombosis

Optimizing CV Risk in Hospitalized Patients - tri-ist.com IST PDFs of PPTs/Day 2... · Optimizing CV Risk in Hospitalized Patients ... A patient had an NSTEMI with a ... Lp-PLA2 Thrombosis

Financial statements - Yara International · 2018-03-16 · Operating income 5 14,104 10,305 Share of net income in equity-accounted investees 14,17 (310) 786 Interest income and

Financial statements - Yara International · 2018-03-16 · Operating income 5 14,104 10,305 Share of net income in equity-accounted investees 14,17 (310) 786 Interest income and

Professor Richard Troughton South/Sun_Plenary_0730_Trougton...• 23% CV mortality or HF hospitalization CHARM-Added4 (2003) 2,548 patients Candesartan (ARB) vs • 15% CV mortality

Professor Richard Troughton South/Sun_Plenary_0730_Trougton...• 23% CV mortality or HF hospitalization CHARM-Added4 (2003) 2,548 patients Candesartan (ARB) vs • 15% CV mortality

CV - orc.mums.ac.irorc.mums.ac.ir/images/orc/cv-english/1.pdf · Shoulder Surgery Fellowship Clinique e General, Annecy, France 2007 ... Patients Suffering from Frozen Shoulder. ABJS.

CV - orc.mums.ac.irorc.mums.ac.ir/images/orc/cv-english/1.pdf · Shoulder Surgery Fellowship Clinique e General, Annecy, France 2007 ... Patients Suffering from Frozen Shoulder. ABJS.

CV RISK IN PATIENTS WITH TYPE 2 DIABETES & CVD€¦ · CV RISK IN PATIENTS WITH TYPE 2 DIABETES & CVD Getting to the heart of diabetes Thursday, 18 October 2018 7.00 –8.00pm AEDT.

CV RISK IN PATIENTS WITH TYPE 2 DIABETES & CVD€¦ · CV RISK IN PATIENTS WITH TYPE 2 DIABETES & CVD Getting to the heart of diabetes Thursday, 18 October 2018 7.00 –8.00pm AEDT.

Effect of Dapagliflozin on Atrial Fibrillation in Patients ... · studied the CV efficacy and safety of dapagliflozin in 17,160 patients with type 2 diabetes mellitus (T2DM) and either

Effect of Dapagliflozin on Atrial Fibrillation in Patients ... · studied the CV efficacy and safety of dapagliflozin in 17,160 patients with type 2 diabetes mellitus (T2DM) and either